Highlights

  • Corbevax has been approved as a heterologous booster dose
  • Corbevax approved for all adults in India
  • It can be taken as a booster 6 months after full primary vaccination

Latest news

Bhumi Pednekar loves ghee coffee? Here's how to make the healthy drink

Bhumi Pednekar loves ghee coffee? Here's how to make the healthy drink

Sushmita Sen: ‘I came close to getting married thrice, all three times God saved me’

Sushmita Sen: ‘I came close to getting married thrice, all three times God saved me’

Was Amravati local murdered for post supporting Nupur Sharma?

Was Amravati local murdered for post supporting Nupur Sharma?

'Thor: Love and Thunder:' Five things to know about the Marvel villain Gorr the God Butcher

'Thor: Love and Thunder:' Five things to know about the Marvel villain Gorr the God Butcher

'I take my hat off to the way he played': Paul Collingwood in awe of Rishabh Pant

'I take my hat off to the way he played': Paul Collingwood in awe of Rishabh Pant

Biological E's Corbevax approved Covid-19 booster dose for 18 and above in India

BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country

Biological E Limited on Saturday announced that its COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India (DCGI) as a heterologous booster dose.

A press release from the vaccine maker said the Corbevax can be administered as a booster dose to individuals aged 18 years and above after six months of administration of primary vaccination (two doses) of Covaxin or Covishield vaccines for restricted use in emergency situation.

BE's Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster in the country, it said.

Recently, BE furnished its clinical trials data to the DCGI which after a detailed evaluation and deliberations with Subject Experts Committee, granted their approval for administering Corbevax as a heterologous booster dose to people who have been vaccinated.

BE's clinical trial data showed that its Corbevax booster dose provided significant enhancement in immune response and excellent safety profile required for an effective booster.

Mahima Datla, Managing Director, Biological E Limited, said, "We are very happy with this approval, which will address the need for COVID-19 booster doses in India. We have crossed yet another milestone in our COVID-19 vaccination journey. This approval reflects once again the sustained world-class safety standards and high immunogenicity of Corbevax." BE has conducted a multi-centre Phase-III placebo controlled heterologous booster clinical trial in 416 subjects from 18 to 80 years of age who were previously vaccinated with two doses of either Covishield or Covaxin at least six months prior to the administration of Corbevax as a booster, the release added.

Corbevax is entirely developed and manufactured by BE Limited in association with Texas Children's Hospital and Baylor College of Medicine as a recombinant protein sub-unit vaccine against COVID-19.

BE has supplied 100 million doses of the jab to the Central government so far.

Also Watch| Covid-19: Covaxin gets emergency use nod for 6-12 age group

Up Next

Biological E's Corbevax approved Covid-19 booster dose for 18 and above in India

Biological E's Corbevax approved Covid-19 booster dose for 18 and above in India

China's easing of quarantine period a glimmer towards easing of global isolation?

China's easing of quarantine period a glimmer towards easing of global isolation?

Covid vaccine Covovax gets nod for children aged 7-11 from Indian regulator: reports

Covid vaccine Covovax gets nod for children aged 7-11 from Indian regulator: reports

India tour of England: BCCI scold Team India players for roaming in public

India tour of England: BCCI scold Team India players for roaming in public

Covid vaccines prevented deaths of 42 lakh Indians in 2021: Lancet study

Covid vaccines prevented deaths of 42 lakh Indians in 2021: Lancet study

Long Covid in infected children can last at least two months: Lancet study

Long Covid in infected children can last at least two months: Lancet study

More videos

IND Vs ENG: R Ashwin tests positive for Covid-19, misses London flight

IND Vs ENG: R Ashwin tests positive for Covid-19, misses London flight

Bar suspected to be Covid-19 hotspot, new restrictions imposed in Beijing

Bar suspected to be Covid-19 hotspot, new restrictions imposed in Beijing

Anocovax: India's first Covid vaccine for animals launched

Anocovax: India's first Covid vaccine for animals launched

WHO: Covid-19 cases and deaths falling nearly everywhere

WHO: Covid-19 cases and deaths falling nearly everywhere

Not wearing masks? You can now be removed from the plane

Not wearing masks? You can now be removed from the plane

Maharashtra records 81% rise in daily Covid-19 cases

Maharashtra records 81% rise in daily Covid-19 cases

4-day work week? World's biggest trial begins in UK

4-day work week? World's biggest trial begins in UK

Congress President Sonia Gandhi tests positive for Covid-19, has mild fever

Congress President Sonia Gandhi tests positive for Covid-19, has mild fever

Is Covid-19 situation getting better in North Korea? This is what WHO said

Is Covid-19 situation getting better in North Korea? This is what WHO said

Covid-19 outbreak: here's what North Koreans have been told by Kim Jong Un regime

Covid-19 outbreak: here's what North Koreans have been told by Kim Jong Un regime

Editorji Technologies Pvt. Ltd. © 2022 All Rights Reserved.